128 related articles for article (PubMed ID: 12556098)
21. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
22. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
[TBL] [Abstract][Full Text] [Related]
23. Association of ovarian tumor epithelium coexpressing HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes.
Matsushita N; Ghazizadeh M; Konishi H; Araki T
J Nippon Med Sch; 2003 Feb; 70(1):40-4. PubMed ID: 12646975
[TBL] [Abstract][Full Text] [Related]
24. Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma.
Sheu BC; Hsu SM; Ho HN; Lin RH; Torng PL; Huang SC
Cancer; 1999 Oct; 86(8):1537-43. PubMed ID: 10526283
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
[TBL] [Abstract][Full Text] [Related]
26. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
[TBL] [Abstract][Full Text] [Related]
27. Combined Immunoscore of CD103 and CD3 Identifies Long-Term Survivors in High-Grade Serous Ovarian Cancer.
Bösmüller HC; Wagner P; Peper JK; Schuster H; Pham DL; Greif K; Beschorner C; Rammensee HG; Stevanović S; Fend F; Staebler A
Int J Gynecol Cancer; 2016 May; 26(4):671-9. PubMed ID: 26905331
[TBL] [Abstract][Full Text] [Related]
28. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
Mohme M; Schliffke S; Maire CL; Rünger A; Glau L; Mende KC; Matschke J; Gehbauer C; Akyüz N; Zapf S; Holz M; Schaper M; Martens T; Schmidt NO; Peine S; Westphal M; Binder M; Tolosa E; Lamszus K
Clin Cancer Res; 2018 Sep; 24(17):4187-4200. PubMed ID: 29444930
[No Abstract] [Full Text] [Related]
29. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.
Santin AD; Bellone S; Palmieri M; Bossini B; Cane' S; Bignotti E; Roman JJ; Cannon MJ; Pecorelli S
Int J Gynecol Cancer; 2004; 14(1):64-75. PubMed ID: 14764031
[TBL] [Abstract][Full Text] [Related]
30. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
[TBL] [Abstract][Full Text] [Related]
31. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.
Grimm M; Feyen O; Hofmann H; Teriete P; Biegner T; Munz A; Reinert S
Tumour Biol; 2016 Mar; 37(3):3807-16. PubMed ID: 26474587
[TBL] [Abstract][Full Text] [Related]
32. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.
Melichar B; Nash MA; Lenzi R; Platsoucas CD; Freedman RS
Clin Exp Immunol; 2000 Jan; 119(1):19-27. PubMed ID: 10606960
[TBL] [Abstract][Full Text] [Related]
33. Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer.
De La Motte Rouge T; Corné J; Cauchois A; Le Boulch M; Poupon C; Henno S; Rioux-Leclercq N; Le Pabic E; Laviolle B; Catros V; Levêque J; Fautrel A; Le Gallo M; Legembre P; Lavoué V
Mol Cancer Res; 2019 Dec; 17(12):2537-2548. PubMed ID: 31537619
[TBL] [Abstract][Full Text] [Related]
34. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.
Lai P; Rabinowich H; Crowley-Nowick PA; Bell MC; Mantovani G; Whiteside TL
Clin Cancer Res; 1996 Jan; 2(1):161-73. PubMed ID: 9816103
[TBL] [Abstract][Full Text] [Related]
35. [Clinicopathological significance of cytotoxic lymphocytes in breast cancer and draining lymph nodes].
Wang HY; He JJ; Shi QF; Lai BC; Ding HY; Zheng J; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2009 Jun; 38(6):384-8. PubMed ID: 19781344
[TBL] [Abstract][Full Text] [Related]
36. [Lymphocyte activation markers in patients with ovarian cancer].
Nowicka A; Rogala E; Bednarek W; Barczyński B; Wertel I; Piekarczyk W; Kotarski J
Ginekol Pol; 2012 Oct; 83(10):737-43. PubMed ID: 23383558
[TBL] [Abstract][Full Text] [Related]
37. Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
Giraldo NA; Becht E; Vano Y; Petitprez F; Lacroix L; Validire P; Sanchez-Salas R; Ingels A; Oudard S; Moatti A; Buttard B; Bourass S; Germain C; Cathelineau X; Fridman WH; Sautès-Fridman C
Clin Cancer Res; 2017 Aug; 23(15):4416-4428. PubMed ID: 28213366
[No Abstract] [Full Text] [Related]
38. Tumor lymphocytes in patients with advanced ovarian cancer: changes during in vitro culture and implications for immunotherapy.
Han X; Papadopoulos AJ; Ruparelia V; Devaja O; Raju KS
Gynecol Oncol; 1997 Jun; 65(3):391-8. PubMed ID: 9190963
[TBL] [Abstract][Full Text] [Related]
39. A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases.
Montfort A; Pearce O; Maniati E; Vincent BG; Bixby L; Böhm S; Dowe T; Wilkes EH; Chakravarty P; Thompson R; Topping J; Cutillas PR; Lockley M; Serody JS; Capasso M; Balkwill FR
Clin Cancer Res; 2017 Jan; 23(1):250-262. PubMed ID: 27354470
[TBL] [Abstract][Full Text] [Related]
40. Expression of inhibitory receptors in natural killer (CD3(-)CD56(+)) cells and CD3(+)CD56(+) cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinoma.
Yuen MF; Norris S
Clin Immunol; 2001 Dec; 101(3):264-9. PubMed ID: 11726217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
